Heim1099 • HKG
add
Sinopharm Group Co Ltd
Við síðustu lokun
18,37 $
Árabil
16,74 $ - 22,35 $
Markaðsvirði
57,70 ma. HKD
Meðalmagn
5,61 m.
V/H-hlutf.
7,72
A/V-hlutfall
4,02%
Aðalkauphöll
HKG
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CNY) | jún. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 144,38 ma. | -2,09% |
Rekstrarkostnaður | 6,36 ma. | -6,80% |
Nettótekjur | 2,00 ma. | -12,11% |
Hagnaðarhlutfall | 1,39 | -9,74% |
Hagnaður á hvern hlut | — | — |
EBITDA | 5,65 ma. | -6,41% |
Virkt skatthlutfall | 27,77% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CNY) | jún. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 47,16 ma. | 8,83% |
Heildareignir | 420,17 ma. | -2,19% |
Heildarskuldir | 290,70 ma. | -5,36% |
Eigið fé alls | 129,47 ma. | — |
Útistandandi hlutabréf | 3,12 ma. | — |
Eiginfjárgengi | 0,71 | — |
Arðsemi eigna | 2,71% | — |
Ávöxtun eigin fjár | 5,26% | — |
Peningaflæði
Breyting á handbæru fé
| (CNY) | jún. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 2,00 ma. | -12,11% |
Handbært fé frá rekstri | 164,40 m. | -97,47% |
Reiðufé frá fjárfestingum | -1,15 ma. | 11,27% |
Reiðufé frá fjármögnun | 2,70 ma. | 548,42% |
Breyting á handbæru fé | 1,71 ma. | -62,83% |
Frjálst peningaflæði | -9,01 ma. | — |
Um
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Stofnsett
2003
Vefsvæði
Starfsfólk
100.251
